Browse News
Filter News
Found 14 articles
-
Kiora Pharmaceuticals Appoints Melissa Tosca as Executive Vice President of Finance
9/13/2022
Salt Lake City, Utah--(Newsfile Corp. - September 13, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") has appointed Melissa Tosca as Executive Vice President of Finance.
-
Neomorph, Inc. Announces Appointment of Chief Financial Officer
9/7/2022
Neomorph, Inc., a venture backed biotechnology company solving critical problems in human health through the discovery and development of innovative new medicines against ‘undruggable targets,’ announced the appointment of Bell Zhong as the company’s Chief Financial Officer.
-
Neomorph, Inc. to Participate in Upcoming Guggenheim Healthcare Talks – Targeted Protein Degradation Day
3/10/2022
Neomorph, Inc., a rapidly growing biotechnology company comprised of industry leading experts in the field of targeted protein degradation (TPD), today announced that it will participate in an upcoming virtual investor conference.
-
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
-
BioSpace Announces Top New Biopharma Companies to Watch in 2022
1/5/2022
BioSpace, Inc., the leading life sciences news and careers site, has announced their selections for the industry’s most exciting up-and-coming companies in 2022.
-
Philip Chamberlain Named as Chief Executive Officer of Neomorph
11/29/2021
Neomorph, Inc., a venture backed biotechnology company solving critical problems in human health through the discovery and development of innovative new medicines against ‘undruggable targets’, announced that its board of directors has appointed Philip Chamberlain, D.Phil. as Chief Executive Officer.
-
Although they don’t necessarily agree on numbers, most reports indicate that 2020 was not a particularly good year for mergers and acquisitions in the biopharma industry.
-
Biopharma Money on the Move: December 16-22
12/23/2020
A roundup of the latest biopharma companies scooping up cash through IPOs and financing rounds. -
It is already a very Merry Christmas for brand new San Diego-based biotech Neomorph, Inc., which found $109 million under the tree in a Series A financing to advance its proprietary protein degradation platform and programs.
-
Neomorph, Inc. Announces $109 Million Series A Financing to Advance Proprietary Protein Degradation Platform and Programs
12/22/2020
Neomorph, Inc. announced a $109 million Series A financing to advance a proprietary targeted protein degradation platform and specific programs. Deerfield Management Company established Neomorph earlier this year with scientific founders Phil Chamberlain, DPhil; Eric Fischer, PhD; Benjamin Ebert, MD, PhD; and Scott Armstrong, MD, PhD.
-
Blueprint Medicines Presents Foundational Preclinical Data Supporting the Development of BLU-782, a Highly Selective ALK2 Inhibitor, for the Treatment of Patients with Fibrodysplasia Ossificans Progressiva
10/1/2018
Plan to Initiate Phase 1 Clinical Trial in Healthy Volunteers in First Quarter of 2019
-
IDbyDNA Raises $9 Million In Series A To Bring Precision Medicine To Infectious Diseases
9/8/2016
-
H3 Biomedicine Publishes Preclinical Data Describing Mechanistic Insights Into Splicing Factor Mutations In Multiple Cancers
10/26/2015
-
North Carolina Research Campus Release: Loraine Lab: Answering Fundamental Questions in Plant Biology
9/8/2011